Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;39(3):527-538.
doi: 10.1007/s10096-019-03754-1. Epub 2019 Dec 18.

Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients

Affiliations

Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients

Julien Cazavet et al. Eur J Clin Microbiol Infect Dis. 2020 Mar.

Abstract

Linezolid is an antibiotic used against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. Its primary adverse effect is haematotoxicity. The objective of this study was to analyse the risk factors for onset of thrombocytopenia in critically ill patients treated with linezolid. This was a retrospective, single-centre study of 72 patients. Platelets were measured from D0 to D20 after the start of treatment. The risk factors for thrombocytopenia were identified using a multivariate logistic regression analysis following a Monte Carlo simulation. Following ROC curve analysis, a baseline platelet count lower than 108 × 109/L and a Cmin higher than 4 mg/L, with respective odds ratios of 117 (95% CI [97-206]) and 3 (95% CI [1.5-6.2]) in the simulated population, were identified as risk factors. Among the source population patients combining these 2 factors, a significantly higher number developed thrombocytopenia (66.7% vs. 33.3%, p = 0.0042). A baseline platelet count lower than 108 × 109/L and a Cmin higher than 4 mg/L are risk factors for the onset of thrombocytopenia in critically ill patients treated with linezolid.

Keywords: Haematotoxicity; Linezolid; Thrombocytopenia.

PubMed Disclaimer

References

    1. J Antimicrob Chemother. 2013 Sep;68(9):2128-33 - PubMed
    1. Eur J Clin Pharmacol. 2014 Jan;70(1):23-8 - PubMed
    1. Int J Antimicrob Agents. 2010 Aug;36(2):179-81 - PubMed
    1. J Antimicrob Chemother. 2005 Aug;56(2):440-1 - PubMed
    1. Nephron. 1976;16(1):31-41 - PubMed

LinkOut - more resources